search
Back to results

Combination of Corticotherapy and Intensive Insulin Therapy for Septic Shock (COIITSS)

Primary Purpose

Septic Shock

Status
Completed
Phase
Phase 3
Locations
France
Study Type
Interventional
Intervention
recombinant human insulin
hydrocortisone
fludrocortisone
Hydrocortisone
Sponsored by
University of Versailles
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Septic Shock focused on measuring septic shock, adrenal insufficiency, glucose control, mineralocorticoids

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Patients admitted in intensive care units for septic shock and meeting all following criteria Proven infection Need for vasopressor to maintain systemic arterial tension above 90 mmHg Multiple organ dysfunction as defined by a SOFA score ³ 8. Need for treatment with moderate dose of corticosteroids Exclusion Criteria: One of the following : Pregnancy Less than 18 years old Moribund (i.e. expected to die on day of intensive care unit admission)

Sites / Locations

  • Hôpital Avicenne
  • Hôpital Jean Verdier
  • CHU Grenoble
  • Hôpital central
  • Hôpital Saint Louis
  • Hôpital Bichat Claude Bernard
  • hôpital Cochin
  • Hôpital Delafontaine

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Active Comparator

Experimental

Experimental

Experimental

Arm Label

1

2

3

4

Arm Description

Hydrocortisone and convention glycemic control

Hydrocortisone and fludrocortisone and conventional glucose control

Hydrocortisone and intensive insulin therapy

hydrocortisone, fludrocortisone and intensive insulin therapy

Outcomes

Primary Outcome Measures

In-hospital mortality

Secondary Outcome Measures

Secondary outcomes :
90-day and 180-day mortality.
Duration of life-supporting treatments (i.e. vasopressors and mechanical ventilation)
Time to resolve multiple organ dysfunction, i.e. to obtain a SOFA score < 8
Hospital length of stay.
Number of hypoglycaemic events (blood glucose < 4 mmol/l) during insulin infusion
Muscle weakness at discharge from intensive care unit, 90-day and 180-day
Post traumatic stress disorders

Full Information

First Posted
April 27, 2006
Last Updated
April 5, 2010
Sponsor
University of Versailles
Collaborators
Assistance Publique - Hôpitaux de Paris
search

1. Study Identification

Unique Protocol Identification Number
NCT00320099
Brief Title
Combination of Corticotherapy and Intensive Insulin Therapy for Septic Shock
Acronym
COIITSS
Official Title
Phase 3 Study of Corticotherapy (Hydrocortisone Alone Versus Hydrocortisone Plus Fludrocortisone) Versus Corticotherapy Plus Intensive Insulin Therapy for Septic Shock
Study Type
Interventional

2. Study Status

Record Verification Date
April 2010
Overall Recruitment Status
Completed
Study Start Date
January 2006 (undefined)
Primary Completion Date
January 2009 (Actual)
Study Completion Date
February 2009 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
University of Versailles
Collaborators
Assistance Publique - Hôpitaux de Paris

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study will compare, in adults with septic shock, the safety and efficacy of a combination of moderate doses of corticosteroids and intensive insulin therapy to that of moderate doses of corticosteroids. In addition, this study will compare the efficacy and safety of hydrocortisone alone versus hydrocortisone plus fludrocortisone
Detailed Description
Objectives: Comparison, in patients with septic shock, of efficacy and safety of the combination of moderate doses of corticosteroids and intensive insulin therapy to that of moderate doses of corticosteroids; and of efficacy and safety of hydrocortisone alone versus hydrocortisone plus fludrocortisone Methods Study design : This is a multicenter, prospective, randomised trial on parallel groups Study treatments : Experimental arm A: A1=50 mg iv every 6 hours of hydrocortisone (hemisuccinate), 50µg through the nasogastric tube of 9 alpha fludrocortisone, for 7 days AND strict control of blood glucose levels with a target of 4,4 to 6 mmol/L using continuous iv infusion of insulin up to intensive care unit discharge. A2=50 mg iv every 6 hours of hydrocortisone (hemisuccinate) for 7 days AND strict control of blood glucose levels with a target of 4,4 to 6 mmol/L using continuous iv infusion of insulin up to intensive care unit discharge. Control arm B: B1:50 mg iv every 6 hours of hydrocortisone (hemisuccinate), 50µg through the nasogastric tube of 9 alpha fludrocortisone, for 7 days. B2:50 mg iv every 6 hours of hydrocortisone (hemisuccinate)for 7 days. Study Primary outcome : In-hospital mortality Sample size calculation : The expected in-hospital mortality rate in the control group is 50%. To detect an absolute reduction in in-hospital mortality rate of 12.5 %, that is 37.5% in the experimental arm versus 50% in the control arm, and considering risk alpha of 0,05 and a risk beta of 0,20, 254 patients per treatment arms are needed, for a total of 508 patients.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Septic Shock
Keywords
septic shock, adrenal insufficiency, glucose control, mineralocorticoids

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Factorial Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
508 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Active Comparator
Arm Description
Hydrocortisone and convention glycemic control
Arm Title
2
Arm Type
Experimental
Arm Description
Hydrocortisone and fludrocortisone and conventional glucose control
Arm Title
3
Arm Type
Experimental
Arm Description
Hydrocortisone and intensive insulin therapy
Arm Title
4
Arm Type
Experimental
Arm Description
hydrocortisone, fludrocortisone and intensive insulin therapy
Intervention Type
Drug
Intervention Name(s)
recombinant human insulin
Intervention Description
intensive insulin therapy as a continuous infusion to maintain blood glucose levels between 4 and 6 mmol/l
Intervention Type
Drug
Intervention Name(s)
hydrocortisone
Intervention Description
50 mg as iv bolus every 6 hours for 7 days
Intervention Type
Drug
Intervention Name(s)
fludrocortisone
Intervention Description
50 µg once a day via a nasogastric tube for seven days
Intervention Type
Drug
Intervention Name(s)
Hydrocortisone
Intervention Description
hydrocortisone 50mg q6 for 7 days
Primary Outcome Measure Information:
Title
In-hospital mortality
Time Frame
Day 180
Secondary Outcome Measure Information:
Title
Secondary outcomes :
Time Frame
Day 180
Title
90-day and 180-day mortality.
Time Frame
Day 180
Title
Duration of life-supporting treatments (i.e. vasopressors and mechanical ventilation)
Time Frame
Day 180
Title
Time to resolve multiple organ dysfunction, i.e. to obtain a SOFA score < 8
Time Frame
Day 180
Title
Hospital length of stay.
Time Frame
Day 180
Title
Number of hypoglycaemic events (blood glucose < 4 mmol/l) during insulin infusion
Time Frame
Day 180
Title
Muscle weakness at discharge from intensive care unit, 90-day and 180-day
Time Frame
Day 180
Title
Post traumatic stress disorders
Time Frame
Day 180

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients admitted in intensive care units for septic shock and meeting all following criteria Proven infection Need for vasopressor to maintain systemic arterial tension above 90 mmHg Multiple organ dysfunction as defined by a SOFA score ³ 8. Need for treatment with moderate dose of corticosteroids Exclusion Criteria: One of the following : Pregnancy Less than 18 years old Moribund (i.e. expected to die on day of intensive care unit admission)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Djillali annane, MD, PhD
Organizational Affiliation
Assistance Publique Hôpitaux de Paris - University of Versailles
Official's Role
Study Chair
Facility Information:
Facility Name
Hôpital Avicenne
City
Bobigny
Country
France
Facility Name
Hôpital Jean Verdier
City
Bondy
Country
France
Facility Name
CHU Grenoble
City
Grenoble
Country
France
Facility Name
Hôpital central
City
Nancy
Country
France
Facility Name
Hôpital Saint Louis
City
Paris
ZIP/Postal Code
75
Country
France
Facility Name
Hôpital Bichat Claude Bernard
City
Paris
Country
France
Facility Name
hôpital Cochin
City
Paris
Country
France
Facility Name
Hôpital Delafontaine
City
Saint Denis
ZIP/Postal Code
93
Country
France

12. IPD Sharing Statement

Citations:
PubMed Identifier
20103758
Citation
COIITSS Study Investigators; Annane D, Cariou A, Maxime V, Azoulay E, D'honneur G, Timsit JF, Cohen Y, Wolf M, Fartoukh M, Adrie C, Santre C, Bollaert PE, Mathonet A, Amathieu R, Tabah A, Clec'h C, Mayaux J, Lejeune J, Chevret S. Corticosteroid treatment and intensive insulin therapy for septic shock in adults: a randomized controlled trial. JAMA. 2010 Jan 27;303(4):341-8. doi: 10.1001/jama.2010.2. Erratum In: JAMA. 2010 May 5;303(17):1698.
Results Reference
result

Learn more about this trial

Combination of Corticotherapy and Intensive Insulin Therapy for Septic Shock

We'll reach out to this number within 24 hrs